…but who doesn’t like a nice long nap?
“Drug Development” in Alzheimer’s can put one to sleep these days. Many things still seem focused on exploiting the Amyloid Cascade Hypothesis. There are a few agents addressing tau protein pathways, or patients’ behavioral issues, but few new intriguing concepts of primary pathophysiology.
Abstracts/ posters for drug development at the AAIC 2023 Meeting appeared in a special supplementary issue of Alzheimer’s & Dementia, June 2023.
Ranging from nicotine [a teaser abstract?], to the positive role of alcohol, fecal transplants to tyrosine kinase inhibitors, sadly nothing was thought newsworthy enough to be included in the AAIC Press Releases this year.
One review [Jeremic] of amyloid beta therapies states: “Thus far, experimental therapies directed against Aβ have not been able to significantly reduce the progress of AD and memory impairment. The majority of therapeutic strategies were focused on amyloid precursor protein processing, and active or passive immunotherapy. Fewer studies evaluated drugs affecting Aβ misfolding, aggregation or clearance.”
Image from Jeremic D, Jimenez-Diaz L and Navarro-Lopez J, “Free Access,” Creative Commons License, A systematic review of therapeutic strategies against amyloid-beta...Alzheimer’s Dement. 2023;19(Suppl. 7):e060438.
This blog can be sleep-inducing, but just think of it as contributing to the reader’s brain glymphatic workout and activation of the brain’s waste management. Makes one wonder if human hibernation wouldn’t help cognition. Back to pandas, they don’t hibernate like other bears do. An AlzheimerGadfly might not hibernate like other Gadflies do….but this one will try hibernation for awhile.
Why does the eye see a thing more clearly in dreams than the imagination when awake? Leonardo da Vinci
When the Napper Awakens, it will be time to share some savory tender bamboo…
